Key Takeaways
- • CapeHaven, a Yale-based biotech venture creation platform, closed its first funding deal in May, securing $3 million toward a $10 million goal, according to the Yale Daily News.
- • The firm was founded by Ranjit Bindra, Kevin Rakin, Seth Herzon, and Mike Dillon, and is designed to turn early Yale research into therapeutic companies.
- • CapeHaven pursues a "multi-asset" model, housing several distinct assets under one parent company that can be monetized through developmental milestones.
- • The platform plans to take on one or two companies per year, providing financial and intellectual capital plus shared operational infrastructure.
- • The founders cite Modifi Bio, co-founded by Bindra and Herzon and acquired by Merck in 2024 for up to $1.3 billion in milestone payments, as the model's precedent.
Summary
CapeHaven, a Yale-based biotech venture creation platform, aims to convert promising Yale life sciences research into early-stage therapeutic companies. According to the Yale Daily News, the company closed its first funding deal in May, securing $3 million on the way to a $10 million fundraising goal. The firm was founded by Ranjit Bindra, a professor of therapeutic radiology and pathology; Kevin Rakin, a co-founder and partner at HighCape Partners; Seth Herzon, a chemistry professor; and Mike Dillon, a manager and board member.
The platform builds on the track record of Modifi Bio, a company Bindra and Herzon co-founded to develop a novel glioblastoma treatment. Merck acquired Modifi in 2024 for up to $1.3 billion in developmental milestone payments. Bindra said building Modifi showed that a therapeutic product requires far more than a promising finding, including a strong team, a focused development plan, capital, and disciplined prioritization of experiments. Rakin, who has worked with Bindra for about 25 years, said the process requires more than venture capital, describing the need to "roll up your sleeves" to move a project out of the academic environment.
After identifying research at Yale, CapeHaven assembles a business plan, financing strategy, and management team. Outside general legal counsel Dormer Stephen described the structure as a "multi-asset play," distinct from the single-asset and platform-science models typical of biotech startups. Under this model, multiple assets sit under one parent company and can be monetized over time through milestones. Stephen said CapeHaven provides both financial and intellectual capital along with shared operational infrastructure.
Rakin said the platform intends to take on one or two companies a year, given that therapeutics often take many years to reach market. He said CapeHaven will both build companies and invest alongside later investors. Key markers for selecting companies include preclinical data supporting future approval, founder passion, and market timing, which Rakin summarized as needing to be neither too early nor too late. CapeHaven's laboratory space is located at 55 Church St., New Haven.
The platform builds on the track record of Modifi Bio, a company Bindra and Herzon co-founded to develop a novel glioblastoma treatment. Merck acquired Modifi in 2024 for up to $1.3 billion in developmental milestone payments. Bindra said building Modifi showed that a therapeutic product requires far more than a promising finding, including a strong team, a focused development plan, capital, and disciplined prioritization of experiments. Rakin, who has worked with Bindra for about 25 years, said the process requires more than venture capital, describing the need to "roll up your sleeves" to move a project out of the academic environment.
After identifying research at Yale, CapeHaven assembles a business plan, financing strategy, and management team. Outside general legal counsel Dormer Stephen described the structure as a "multi-asset play," distinct from the single-asset and platform-science models typical of biotech startups. Under this model, multiple assets sit under one parent company and can be monetized over time through milestones. Stephen said CapeHaven provides both financial and intellectual capital along with shared operational infrastructure.
Rakin said the platform intends to take on one or two companies a year, given that therapeutics often take many years to reach market. He said CapeHaven will both build companies and invest alongside later investors. Key markers for selecting companies include preclinical data supporting future approval, founder passion, and market timing, which Rakin summarized as needing to be neither too early nor too late. CapeHaven's laboratory space is located at 55 Church St., New Haven.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.